COVID-19 boosters offered to anyone ages 18 and older

Translate to Spanish or other 102 languages!

Image for illustration purposes.

Mega Doctor News

- Advertisement -

RIO GRANDE VALLEY, Texas – UT Health RGV is now offering COVID-19 boosters (Pfizer-BioNTech and Moderna) to anyone ages 18 and older.

All fully vaccinated people aged 18+ can get a booster at least 6 months after their second dose of Pfizer or Moderna or at least 2 months after initial dose of Johnson & Johnson.

Community members aged 5+ can get vaccinated at the following locations:

- Advertisement -

EDINBURG

Tuesday, Nov. 30, 1-6 p.m.

HARLINGEN

Wednesday, Dec. 1, 1-6 p.m.

- Advertisement -

MISSION

Wednesday, Dec. 1, 1-6 p.m.

  • V Express Care by UT Health RGV (at H-E-B plus!), located at 2409 East Expressway 83. (By appointment only – call for available dates and times at 956-296-2935.

FOR PARENTS AND GUARDIANS OF CHILDREN AGED 5-11

  • You willreceive a call from 1-833-888-2268 (1-833-UTVACN8 ) upon scheduling your child’s appointment. Please save this phone number 
  • This lower-dose Pfizer vaccine is the only COVID-19 vaccine to be authorized and recommended for use in children aged 5-11 years and should be administered as a two-dose series, three weeks apart — just as it is for people aged 12 and up.
  • Appointments for patient’s second dose will be scheduled on-site. 
  • All children under age 18 must be accompanied by a parent or guardian.

To make an appointment, log onto uthealth.org/vaccine or call 1-833-UTRGVMD.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Texas Adds New Condition to Mandatory Newborn Screening Tests

The Texas Department of State Health Services added a new enzyme deficiency test on June 1, 2026, to its newborn screening panel, meaning that all Texas newborns are now tested for 60 rare, genetic conditions. Tests for hearing loss and critical congenital heart disease are additional point-of-service tests typically conducted by the birthing center. 

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

STHS GME Consortium Encourages Community to “Walk with a Doc”, June 6th

Mega Doctor News In an era defined by high-intensity workouts, wearable fitness trackers and advanced training techniques, one of simplest...

STHS Children’s Marks 20th Anniversary with Gala Honoring Pediatric Providers Behind Its Success

For the past 20 years, South Texas Health System Children’s has stood as a place where compassionate care and clinical excellence come together to create hope for children and their families.
- Advertisement -